Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Not yet recruiting Not applicable Interventional

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy

NCT07885033
View directory record Official record
Conditions
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy, Radiation Toxicity
Interventions
ORAL CARE PRODUCT KIT
Other
Lead sponsor
UNCANCER LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Withdrawn No phase listed Observational

Pharmacokinetic Study of Therapeutic Plasma Exchange

NCT07756242
View directory record Official record
Conditions
Immune-related Adverse Event
Interventions
Spectra Optia Apheresis System
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adverse Events Related to Low Dose Atropine

NCT05683535
View directory record Official record
Conditions
Myopia, Progressive
Interventions
Atropine Sulfate
Drug
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 23, 2026, 10:58 PM EDT
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 23, 2026, 10:58 PM EDT
Active, not recruiting Not applicable Interventional

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT01802346
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational

Can Sleep Apnea Screening Questionnaire Predict Adverse Events in Endoscopic Studies

NCT03436381
View directory record Official record
Conditions
Sleep Apnea, Adverse Event
Interventions
Questionaire
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
350 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 10:58 PM EDT
Active, not recruiting Phase 2 Interventional

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions
Infliximab, Methylprednisolone, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 23, 2026, 10:58 PM EDT
Not listed Phase 3 Interventional

Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults

NCT00008489
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
PharmaResearch
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Which Adverse Events Associated With Dry Needling Should be Included For Informed Consent: A Modified e-Delphi Study

NCT05300815
View directory record Official record
Conditions
Dry Needling
Interventions
Delphi Questionaire
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

Long Term Outcomes After Vestibular Implantation

NCT06500975
View directory record Official record
Conditions
Bilateral Vestibular Hypofunction, Bilateral Vestibular Deficiency, Bilateral Vestibulopathy, Gentamicin Ototoxicity, Aminoglycoside Toxicity, Vestibular Diseases, Sensation Disorders, Labyrinth Diseases, Other Disorders of Vestibular Function
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

NCT05248893
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational Results available

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

NCT03223428
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Xermelo
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 23, 2026, 10:58 PM EDT
Recruiting Phase 2 Interventional

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

NCT03480971
View directory record Official record
Conditions
Mucositis, Nephrotoxicity, Ototoxicity
Interventions
Tempol, Placebo Solution
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
La Jolla, California • Merced, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 23, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

Clinical Study of Smoke-Break Liquid Cigarettes

NCT00715871
View directory record Official record
Conditions
Smoking
Interventions
Nicotine, Smoke-Break nicotine delivery device
Drug · Device
Lead sponsor
Smoke-Break, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
West Allis, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational Results available

Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty

NCT04821245
View directory record Official record
Conditions
Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction
Interventions
Not listed
Lead sponsor
Benaroya Research Institute
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational

Early Detection of Broken Hearts in Cancer Patients

NCT02086695
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 23, 2026, 10:58 PM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

NCT05606757
View directory record Official record
Conditions
Ventral Hernia, Abdominal Hernia
Interventions
BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Mineola, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Low Dose Ketamine Infusion for Analgesia in the Emergency Department to Reduce Side Effects

NCT05518877
View directory record Official record
Conditions
Pain, Acute, Dissociation
Interventions
Ketamine
Drug
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 110 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

NCT04324359
View directory record Official record
Conditions
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions
SURF-201, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Hemet, California • Murrieta, California • Brooksville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 23, 2026, 10:58 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06291220
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Obinutuzumab, ABBV-453
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Billings, Montana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Active, not recruiting Phase 1 Interventional

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
1 Year to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Palo Alto, California • Miami, Florida • Valhalla, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 10:58 PM EDT
Completed No phase listed Observational

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

NCT04283539
View directory record Official record
Conditions
Cancer, Skin Disease, Immunotherapy, Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control
Interventions
systemic corticosteroid or biologic
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 99 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 10:58 PM EDT